FDA Accepts Noven's NDA for an Investigational Nonhormonal Therapy for …

Published November 16, 2012

FDA Accepts Noven's NDA For An Investigational Nonhormonal Therapy For …

Filed under: drug treatment news 2012

12, 2012 /PRNewswire/ — Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that its New Drug Application (NDA) for low-dose mesylate salt of paroxetine (LDMP; 7.5 mg) for the treatment of …
Read more on Sacramento Bee

Tired after cancer treatment? Walking may help

Filed under: drug treatment news 2012

Prior studies point to talk therapy, nutrition counseling and acupuncture as possible ways to ease cancer-related fatigue during or after treatment (see Reuters Health story of October 29, 2012). But light-to-moderate exercise has the advantage of …
Read more on Reuters

Drug Slows Knee Osteoarthritis Progression

Filed under: drug treatment news 2012

12, 2012 — A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say. The drug is called strontium ranelate.
Read more on WebMD